Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 15;5(9):2777-87.
eCollection 2015.

Lewis Y antigen modified CD47 is an independent risk factor for poor prognosis and promotes early ovarian cancer metastasis

Mingzi Tan  1 , Liancheng Zhu  1 , Huiyu Zhuang  2 , Yingying Hao  1 , Song Gao  1 , Shuice Liu  1 , Qing Liu  1 , Dawo Liu  1 , Juanjuan Liu  1 , Bei Lin  1
Affiliations

Lewis Y antigen modified CD47 is an independent risk factor for poor prognosis and promotes early ovarian cancer metastasis

Mingzi Tan et al. Am J Cancer Res. .

Abstract

CD47 is a membrane receptor that belongs to the immunoglobulin superfamily and plays an important role in the mechanisms of tumor immune escape. CD47 participates in tumor immune escape by combining with SIRPα to reduce the phagocytic activity of macrophages. There are six potential N-glycosylation sites on CD47, and glycosylation is known to be necessary for its membrane localization. However, it is still unknown to what extent glycosylation influences CD47 ligand binding properties and subsequent signaling. By using immunoprecipitation and confocal laser scanning microscopy, we showed that CD47 contains Lewis y antigen. Immunohistochemical analysis demonstrated that both the positive expression and the overexpression of CD47 and Lewis y antigen in cancer tissues and borderline tumors were significantly higher than those in benign ovarian tumors and normal ovarian tissues (P < 0.05). A linear correlation between the expression patterns of CD47 and Lewis y antigen was evident (r = 0.47, P < 0.01). The high expression of CD47 and Lewis y antigen showed significant correlations with the clinical pathological parameters of ovarian cancer [International Federation of Gynecology and Obstetrics (FIGO) standards, lymph node metastasis, and degree of differentiation] (P < 0.05). The Cox model and Kaplan-Meier tests showed that high expression of CD47 was an independent adverse risk factor for the prognosis of ovarian cancer. Cases with both high CD47 and Lewis y antigen expression had poor prognoses. Our study demonstrates that Lewis y antigens of CD47 may play a crucial role in the development of ovarian cancer, and could be new targets for immunotherapy for ovarian cancer.

Keywords: CD47; Lewis y; ovarian cancer; prognosis; tumor immune escape.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Coexpression of CD47 and Lewis y antigens in Ovarian cell lines (CAOV3, SKOV3), IgG is negative control (contained only 10 μl CD47 antibody).
Figure 2
Figure 2
The double-labeling immunofluorescence shows the colocalization of CD47 and Lewis y antigen in ovarian cancer cell line CAOV3 and SKOV3 (original magnification ×400). Nucleus (A1, B1), Lewis y antigen (A2, B2), CD47 (A3, B3) and merged image (A4, B4).
Figure 3
Figure 3
Expression of CD47 and Lewis y antigens in ovarian tissue groups. Immunohistochemical staining in ovarian malignant tumor (A, B), borderline tumor (C, D), benign tumor (E, F), and normal ovarian tissue (G, H). CD47 (A, C, E, G) and Lewis y (B, D, F, H; original magnification ×400).
Figure 4
Figure 4
Kaplan-Meier survival analysis: (A) CD47 and (B) Lewis y antigen expression in ovarian cancer. P value, Log rank test.
See this image and copyright information in PMC

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. - PubMed
    1. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273–282. - PMC - PubMed
    1. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–907. - PubMed
    1. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–1111. - PubMed
    1. Ugolini S, Vivier E. Immunology: Natural killer cells remember. Nature. 2009;457:544–545. - PubMed

LinkOut - more resources